Medical/Pharmaceuticals

CBC Group Partners with APG to Launch Healthcare Real Estate Platform and Announce US$500 Million First Close of China Life Science Venture

SHANGHAI, Nov. 14, 2021 /PRNewswire/ --CBC Group ("CBC"), Asia's largest healthcare-dedicated investment firm, announced today a partnership with APG Asset Management ("APG"), the largest pension provider inthe Netherlands, in a newAsia-Pacific healthcare platform, CBC Healthcare Infrastructure P...

2021-11-15 10:08 3525

InnoCare Announces the Clearance of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 by U.S. FDA

BEIJING, Nov. 14, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today the Investigational New Drug (IND) clearance of itsSHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP-189 by the US Food and Drug A...

2021-11-15 08:30 2786

Wision A.I. Achieves CE-MDR Mark Approval for AI-assisted Diagnostic Software Medical Device Supporting Colonoscopy

SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- Wision A.I. Ltd, a startup in the field of artificial intelligence assisted diagnostics for gastrointestinal endoscopy, today announced it received the European CE Mark approval for EndoScreener, its AI-assisted polyp detection software during colonoscopy. ...

2021-11-15 08:30 2517

Gannex Announces China NMPA Approved Phase II and III Protocols of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis

SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the protocols of Phase II and III clinical trials of ASC42 to treat patients with primary biliary cholangitis (PBC) has been approved by China National ...

2021-11-15 08:30 3508

Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021

-ATG-101, a novel PD-L1/4-1BB bispecific antibody, shows potent in vivo anti-tumor efficacy in checkpoint inhibitor resistant/relapsed models while mitigating liver toxicity risk, computational analysis adds support to dosing strategy -ATG-017, an ERK1/2 inhibitor, in vivo combination supports c...

2021-11-15 08:25 3804

Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology

SAN FRANCISCO and SUZHOU, China, Nov. 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...

2021-11-15 08:00 3720

$5M Boost to Innovation in Australia with New Illumina Genomics Lab

New laboratory opens in Melbourne Biomedical Precinct to accelerate the adoption of genomics in healthcare and agriculture inAustralia. MELBOURNE, Australia, Nov. 15, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), the global leader in genomics, today announced the opening of a new, fully eq...

2021-11-15 06:14 7112

Ascensia Diabetes Care Announce Winner of This is Diabetes Art and Photo Competition

BASEL, Switzerland, Nov. 14, 2021 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, makers of CONTOUR® blood glucose monitoring (BGM) system portfolio and distributors of the Eversense® continuous glucose monitoring (CGM) system, has announced the winner of its This is Diabe...

2021-11-14 15:00 3188

China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results

HAIKOU, China, Nov. 12, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI)  ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the financial results for the qu...

2021-11-13 05:30 5487

Treadwell Therapeutics Announces A Presentation at the 2021 SITC Annual Meeting Featuring a Clinical Trial Update on CFI-402411, a First-in-Class HPK1 inhibitor

NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced a presentation for the Company's CFI-402411 program, an oral, first-in-class inhibitor ofHematopoietic Progenitor Kinase...

2021-11-13 02:56 5370

Global Accelerated Ventures, ACTUAL, and Bioassets Partner to Work With Enterprises to Make Total Decarbonization Possible

HIGH QUALITY, CERTIFIED CREDITS COMPLEMENT MEANINGFUL EMISSIONS REDUCTIONS FOR ENTERPRISES TO MEET THEIR NET-ZERO MANDATES GLASGOW, Scotland, Nov. 12, 2021 /PRNewswire/ -- Global Accelerated Ventures (GAV) and ACTUAL are partnering with Bioassets, to integrate high quality, provenanced carbon cr...

2021-11-12 23:20 6989

Kintor Pharma Announces Dosing of First Patient in Phase II Clinical Trial of KX-826 for the Treatment of Androgenic Alopecia Female Patients in China

SUZHOU, China, Nov. 12, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the company has dosed the first patient in its phase II clinical ...

2021-11-12 14:17 2476

InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development

BEIJING, Nov. 12, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company executives will attend the upcoming investor conferences organized by Goldman Sachs and Morgan Stanley to share company's latest development. Details are as follows: ...

2021-11-12 14:14 2300

The New Era Biotechnology deepens cooperation between China and Belarus in the Great Stone China Belarus Industrial Park (CBIP)

MINSK, Belarus, Nov. 12, 2021 /PRNewswire/ -- As an enterprise in CBIP, the New Era Biotechnology Co., Ltd. participated in the fourth edition of the China International Import Expo (CIIE) which opened inShanghai on November 5, 2021.

2021-11-12 09:11 2891

Hetero and Shenzhen Beimei Pharmaceuticals launch antiviral drug Oselavir® in China

Oseltamivir phosphate is used in the treatment of acute uncomplicated influenza infection in adults, adolescents and children BEIJING, Nov. 12, 2021 /PRNewswire/ -- Hetero, a globally renowned vertically integrated pharmaceutical organization and Shenzhen Beimei Pharmaceuticals jointly announced...

2021-11-12 09:00 4201

Recbio Announces Promising Preliminary Results From First-in-Human Study of a COVID-19 Vaccine Candidate With Novel Adjuvant BFA03

* Well tolerated and good safety profile, no SAE or TEAE leading to early discontinuation, no abnormal vital signs/laboratory testing results with clinical significance * 20μg ReCOV induced high titer of anti-SARS-CoV-2 neutralizing antibodies, with at least comparable level than published da...

2021-11-12 07:55 4274

Planet Innovation acquires BIT Group's North American operations, doubling its medtech manufacturing capacity

MELBOURNE, Australia, Nov. 11, 2021 /PRNewswire/ -- Planet Innovation (PI) has acquired the North American operations of global regulated medical device manufacturer, BIT Analytical Instruments GmbH. The acquisition solidifies PI's commitment to grow its US manufacturing capabilities to suppor...

2021-11-12 07:44 2703

Tabernacle Health Group Launches Revolutionary Immunity Booster. Natural Health Supplement Avrocil (TM) Treats Cold and Flu Symptoms caused by Upper Respiratory Tract Infections

SINGAPORE, Nov. 11, 2021 /PRNewswire/ -- The pandemic sped up participation in virtual exercise classes acrossthe United States, as countless fitness enthusiasts switched to indoor workouts to avoid viruses, such as those that lead to accelerated upper respiratory tract infections, whose sympto...

2021-11-12 02:00 2382

Patients benefited from telemedicine during COVID-19, says new white paper from Healint

* Longitudinal surveys conducted via HeRO™, Healint's proprietary real-world patient insights platform, reveal that 84% would choose telemedicine if it was available, with a preference for follow-up consultations * A 9-month follow-up questionnaire was sent to evaluate changes in patients' ex...

2021-11-11 23:15 2502

Lunit Presents Studies at SITC 2021, Highlighting the Effectiveness of AI in Predicting Response to Immunotherapy in a Clinical Trial Setting

-  Lunit to present three abstracts about its AI biomarker platform Lunit SCOPE IO, also to be  demonstrated during the event in booth #423 -  One immunotherapy combination study adds significant evidence for the potential value of using Lunit SCOPE IO in clinical practice to predict patient res...

2021-11-11 23:00 2020
1 ... 605606607608609610611 ... 646